rAAV-microdystrophin gene therapy (JCR Pharmaceuticals/Nippon Medical School/National institute of Neuroscience)

N/A

Report date: 2025/03/19 18:27:05

Base Information

Drug NamerAAV-microdystrophin gene therapy (JCR Pharmaceuticals/Nippon Medical School/National institute of Neuroscience)
Drug Alias NamerAAV9-microdystrophin gene therapy (JCR Pharmaceuticals/Nippon Medical School/National institute of Neuroscience)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionDystrophin expression stimulants
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJcr Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNippon Medical School FoundationJapan National Institute of NeuroscienceJcr Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A